This study provides initial proof-of-concept data that suggest that STS inhibition is capable of reducing tumour proliferation as measured by 18F-FLT-PET in vivo, and in tumour biopsies by changes in Ki-67 in a cohort of previously untreated patients with breast cancer. This evidence concerns the gene STS and breast cancer.